Waltham, Mass. — October 3, 2025 — Leads & Copy — Xilio Therapeutics, Inc. (Nasdaq: XLO) will present multiple upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 6-9, 2025 at the Gaylord National Convention Center in National Harbor, Maryland.
Xilio plans to present clinical data for vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, and efarindodekin alfa (XTX301), a tumor-activated IL-12, and plans to present preclinical data highlighting the company’s masked T cell engager programs.
Poster presentation details, as follows:
Title: ctDNA as a Potential Surrogate Biomarker for Response to Combination Vilastobart and Atezolizumab in Heavily Pretreated Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Abstract Number: 541
Presentation Date: Friday, Nov. 7, 2025
Poster Hall Hours: 9:00 a.m.-7:00 p.m. EST
Location: Gaylord Exhibit Halls A & B1
Title: XTX301, a Tumor-Activated Interleukin-12 (IL-12), Demonstrated IL-12 Pharmacology in Patients with Advanced Solid Tumors: Pharmacodynamic Data from First-in-Human Phase 1 Study
Abstract Number: 567
Presentation Date: Friday, Nov. 7, 2025
Poster Hall Hours: 9:00 a.m.-7:00 p.m. EST
Location: Gaylord Exhibit Halls A & B1
Title: Masked T Cell Engagers Designed to Drive Potent Synthetic Anti-Tumor Immunity with Favorable Tolerability
Abstract Number: 972
Presentation Date: Saturday, Nov. 8, 2025
Poster Hall Hours: 9:00 a.m.-8:40 p.m. EST
Location: Gaylord Exhibit Halls A & B1
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment.
Investor Contact:
investors@xiliotx.com
Media Contact:
Josie Butler, 1AB
josie@1abmedia.com
Source: Xilio Therapeutics, Inc.
